[HTML][HTML] The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Pre-existing cross-reactive immune responses to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by …
coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by …
[HTML][HTML] SARS-CoV-2 mutations and their impact on diagnostics, therapeutics and vaccines
S Thakur, S Sasi, SG Pillai, A Nag, D Shukla… - Frontiers in …, 2022 - frontiersin.org
With the high rate of COVID-19 infections worldwide, the emergence of SARS-CoV-2
variants was inevitable. Several mutations have been identified in the SARS-CoV-2 …
variants was inevitable. Several mutations have been identified in the SARS-CoV-2 …
[HTML][HTML] Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
RT Shroff, P Chalasani, R Wei, D Pennington… - Nature medicine, 2021 - nature.com
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
shown high efficacy, but immunocompromised participants were excluded from controlled …
shown high efficacy, but immunocompromised participants were excluded from controlled …
[HTML][HTML] Functional SARS-CoV-2-specific immune memory persists after mild COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is causing a
global pandemic, and cases continue to rise. Most infected individuals experience mildly …
global pandemic, and cases continue to rise. Most infected individuals experience mildly …
SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …
[HTML][HTML] Humoral responses and serological assays in SARS-CoV-2 infections
Y Galipeau, M Greig, G Liu, M Driedger… - Frontiers in …, 2020 - frontiersin.org
In December 2019, the novel betacoronavirus Severe Acute Respiratory Disease
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …
COVID-19 antibody tests and their limitations
G Liu, JF Rusling - ACS sensors, 2021 - ACS Publications
COVID-19, caused by the SARS-CoV-2 virus, has developed into a global health crisis,
causing over 2 million deaths and changing people's daily life the world over. Current main …
causing over 2 million deaths and changing people's daily life the world over. Current main …
[HTML][HTML] Humoral signatures of protective and pathological SARS-CoV-2 infection in children
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to
spread relentlessly, associated with a high frequency of respiratory failure and mortality …
spread relentlessly, associated with a high frequency of respiratory failure and mortality …
[HTML][HTML] Review of current COVID-19 diagnostics and opportunities for further development
Y Mardian, H Kosasih, M Karyana, A Neal… - Frontiers in …, 2021 - frontiersin.org
Diagnostic testing plays a critical role in addressing the coronavirus disease 2019 (COVID-
19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV …
19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV …
[HTML][HTML] A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
C Wang, R van Haperen, J Gutiérrez-Álvarez… - Nature …, 2021 - nature.com
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell
entry and the focus for development of protective antibodies and vaccines. Structural studies …
entry and the focus for development of protective antibodies and vaccines. Structural studies …